Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

YieldMax NVDA Option Income Strategy ETFTrade
DENTSPLY SIRONA IncTrade

Price performance (Past 24H)

Key statistics

YieldMax NVDA Option Income Strategy ETF vs DENTSPLY SIRONA Inc — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $12.6 (market cap $1.45B), while DENTSPLY SIRONA Inc trades at $8.83 (market cap $1.73B). The key difference: DENTSPLY SIRONA Inc is the larger of the two by market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while YieldMax NVDA Option Income Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax NVDA Option Income Strategy ETF for 43 Days and DENTSPLY SIRONA Inc for 72 Days on average.

NVDYXRAY
Market Cap
$1.45B$1.73B
Volume
1,943,7396,198,582
Sector
Income / Options OverlayHealth
52-Week High
$17.21$14.68
52-Week Low
$11.58$8.52
Typical Hold Time
43 Days72 Days
Enterprise Value
—$3.80B
Dividend Yield
—5.04%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax NVDA Option Income Strategy ETF

NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $12.64, down 2.84% on the day amid a bearish technical signal. The fund generates income through options on NVIDIA stock but faces headwinds from declining volatility, which caps upside participation and has led to recent analyst downgrades. Weekly dividend distributions continue, but concerns over net asset value erosion persist.

The outlook for NVDY is cautious, as its high distribution yield comes with structural limitations on capital appreciation. Investment opportunity lies in income generation for risk-tolerant investors, but risks include NAV erosion and dependency on NVIDIA's volatility. Analyst sentiment has shifted to hold, reflecting diminished attractiveness amid lower option premiums.

DENTSPLY SIRONA Inc

DENTSPLY SIRONA (XRAY) trades at $8.54, near its 52-week low, with bearish technical indicators and mixed fundamentals. The company reported Q2 2026 EPS of $0.52 beating expectations but revenue declined 4.1% year-over-year. Net income remains negative at -$598 million for 2025, though margins show slight improvement. Analyst consensus is mixed with 37.5% buy ratings but a $13.40 price target suggesting 57% upside potential from current levels.

The stock presents a high-risk turnaround opportunity with significant upside if management's restructuring efforts succeed, but faces headwinds from declining sales, margin pressure, and competitive challenges in dental markets. Institutional ownership changes and ongoing transformation investments create both uncertainty and potential for recovery.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NVDY
30% Buy70% Sell
Avg holding period · 43 Days
XRAY

No sentiment data available yet.

Top news

Latest headlines on both assets

About YieldMax NVDA Option Income Strategy ETF

NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.

Read more on NVDY →

About DENTSPLY SIRONA Inc

Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters

Read more on XRAY →